PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molmedLink to Publisher's site
 
Mol Med. 1995 September; 1(6): 647–658.
PMCID: PMC2229988

Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate.

Abstract

BACKGROUND: Transgenic mice bearing a murine immunoglobulin enhancer/c-myc fusion transgene (Emu-myc) provide a useful model for Burkitt's lymphoma. MATERIALS AND METHODS: Groups of 12 Emu-myc mice were treated prophylactically for 6 weeks after weaning with anti-c-myc DNA phosphorothioate (20 mg/kg/day), scrambled control DNA, or saline, delivered by micro-osmotic pumps. RESULTS: Half of the mice treated with saline or scrambled control DNA displayed palpable tumors by 8-9 weeks after birth, and 95% of them did so by 16 weeks, but 75% of the mice treated with antisense DNA were still free of tumors at the age of 26 weeks. Antisense therapy ablated MYC antigen in the spleens of tumor-bearing mice. Plasma physiological parameters indicated no acute toxicity. CONCLUSIONS: Long-term tumor resistance after anti-c-myc DNA therapy implies induction of a host response. Prophylactic anti-c-myc DNA therapy might prevent lymphoma in asymptomatic individuals displaying c-myc translocations.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 1990;55:133–270. [PubMed]
  • Bishop JM. Molecular themes in oncogenesis. Cell. 1991 Jan 25;64(2):235–248. [PubMed]
  • Corcoran LM, Cory S, Adams JM. Transposition of the immunoglobulin heavy chain enhancer to the myc oncogene in a murine plasmacytoma. Cell. 1985 Jan;40(1):71–79. [PubMed]
  • Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988 Feb 1;167(2):353–371. [PMC free article] [PubMed]
  • Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature. 328(6129):445–449. [PubMed]
  • Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1028–1032. [PubMed]
  • Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol. 1988 Feb;8(2):963–973. [PMC free article] [PubMed]
  • Harel-Bellan A, Ferris DK, Vinocour M, Holt JT, Farrar WL. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol. 1988 Apr 1;140(7):2431–2435. [PubMed]
  • Wickstrom EL, Bacon TA, Gonzalez A, Lyman GH, Wickstrom E. Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells. In Vitro Cell Dev Biol. 1989 Mar;25(3 Pt 1):297–302. [PubMed]
  • McManaway ME, Neckers LM, Loke SL, al-Nasser AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, Magrath IT. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet. 1990 Apr 7;335(8693):808–811. [PubMed]
  • Bacon TA, Wickstrom E. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5' cap region. Oncogene Res. 1991;6(1):13–19. [PubMed]
  • Bacon TA, Wickstrom E. Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia HL-60 cells in both serum-containing and serum-free media. Oncogene Res. 1991;6(1):21–32. [PubMed]
  • Watson PH, Pon RT, Shiu RP. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 1991 Aug 1;51(15):3996–4000. [PubMed]
  • Paria BC, Dey SK, Andrews GK. Antisense c-myc effects on preimplantation mouse embryo development. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10051–10055. [PubMed]
  • Shi Y, Hutchinson HG, Hall DJ, Zalewski A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation. 1993 Sep;88(3):1190–1195. [PubMed]
  • Biro S, Fu YM, Yu ZX, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):654–658. [PubMed]
  • Peña A, Reddy CD, Wu S, Hickok NJ, Reddy EP, Yumet G, Soprano DR, Soprano KJ. Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex. J Biol Chem. 1993 Dec 25;268(36):27277–27285. [PubMed]
  • Cherney BW, Bhatia K, Tosato G. A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12967–12971. [PubMed]
  • Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 1995 Mar 15;55(6):1379–1384. [PubMed]
  • Wickstrom E, Bacon TA, Wickstrom EL. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res. 1992 Dec 15;52(24):6741–6745. [PubMed]
  • Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, Hall DJ, Shaheen F, Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994 Aug;90(2):944–951. [PubMed]
  • Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res. 1993 Feb 1;53(3):577–580. [PubMed]
  • Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11823–11827. [PubMed]
  • Sun LK, Showe LC, Croce CM. Analysis of the 3' flanking region of the human c-myc gene in lymphomas with the t(8;22) and t(2;8) chromosomal translocations. Nucleic Acids Res. 1986 May 27;14(10):4037–4050. [PMC free article] [PubMed]
  • Sinha ND, Biernat J, McManus J, Köster H. Polymer support oligonucleotide synthesis XVIII: use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucleic Acids Res. 1984 Jun 11;12(11):4539–4557. [PMC free article] [PubMed]
  • Sawadogo M, Van Dyke MW. A rapid method for the purification of deprotected oligodeoxynucleotides. Nucleic Acids Res. 1991 Feb 11;19(3):674–674. [PMC free article] [PubMed]
  • Pieles U, Zürcher W, Schär M, Moser HE. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a powerful tool for the mass and sequence analysis of natural and modified oligonucleotides. Nucleic Acids Res. 1993 Jul 11;21(14):3191–3196. [PMC free article] [PubMed]
  • Klempnauer KH, Sippel AE. Subnuclear localization of proteins encoded by the oncogene v-myb and its cellular homolog c-myb. Mol Cell Biol. 1986 Jan;6(1):62–69. [PMC free article] [PubMed]
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. [PubMed]
  • Sarmiento UM, Perez JR, Becker JM, Narayanan R. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev. 1994 Summer;4(2):99–107. [PubMed]
  • Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol. 1993 May 25;45(10):2037–2043. [PubMed]
  • Polakowska RR, Haake AR. Apoptosis: the skin from a new perspective. Cell Death Differ. 1994 Jul;1(1):19–31. [PubMed]
  • Noonberg SB, Garovoy MR, Hunt CA. Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol. 1993 Nov;101(5):727–731. [PubMed]
  • Stec WJ, Grajkowski A, Koziolkiewicz M, Uznanski B. Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates). Nucleic Acids Res. 1991 Nov 11;19(21):5883–5888. [PMC free article] [PubMed]
  • Vyazovkina EV, Savchenko EV, Lokhov SG, Engels JW, Wickstrom E, Lebedev AV. Synthesis of specific diastereomers of a DNA methylphosphonate heptamer, d(CpCpApApApCpA), and stability of base pairing with the normal DNA octamer d(TPGPTPTPTPGPGPC). Nucleic Acids Res. 1994 Jun 25;22(12):2404–2409. [PMC free article] [PubMed]
  • Hughes JA, Avrutskaya AV, Brouwer KL, Wickstrom E, Juliano RL. Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs. Pharm Res. 1995 Jun;12(6):817–824. [PubMed]
  • Yaswen P, Stampfer MR, Ghosh K, Cohen JS. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev. 1993 Spring;3(1):67–77. [PubMed]
  • Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4051–4055. [PubMed]
  • Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546–549. [PubMed]
  • Gaidano G, Parsa NZ, Tassi V, Della-Latta P, Chaganti RS, Knowles DM, Dalla-Favera R. In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection. Leukemia. 1993 Oct;7(10):1621–1629. [PubMed]
  • Prevot S, Raphael M, Fournier JG, Diebold J. Detection by in situ hybridization of HIV and c-myc RNA in tumour cells of AIDS-related B-cell lymphomas. Histopathology. 1993 Feb;22(2):151–156. [PubMed]
  • Iversen PL, Crouse D, Zon G, Perry G. Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. Antisense Res Dev. 1992 Fall;2(3):223–233. [PubMed]
  • Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994 Dec 1;54(23):6228–6234. [PubMed]
  • Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994 Dec 15;54(24):6477–6483. [PubMed]
  • Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science. 1993 Jan 1;259(5091):94–97. [PubMed]
  • Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 1994 Apr 15;54(8):2218–2222. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ